drugset / Trial / NCT03760666
A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
NaSequentialOpen-labelTreatment
Summary
A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects.
Timeline
- Start
- 2018-12-20
- Primary completion
- 2020-12-31
- Completion
- 2021-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brequinar | Small molecule | 200 mg/m2 | Oral |
| Subject | Brequinar | Small molecule | 500 mg/m2 | Oral |
| Subject | Ribavirin | Small molecule | 1000 mg | Oral |